Jupiter Life Line Hospitals: Business Overview & Financial Analysis
Jupiter Life Line Hospitals is a multi-specialty tertiary and quaternary healthcare provider headquartered in Mumbai, Maharashtra. Promoted by Dr. Ajay Thakker and Dr. Ankit Thakker, the company operates a network of multi-specialty hospitals under the "Jupiter" brand across Western India. The healthcare provider offers comprehensive clinical services covering over 30 medical specialties, including organ transplants, cardiology, oncology, neurosciences, orthopaedics, and paediatrics across its operational facilities in Thane, Pune, Indore, and Dombivli.
Operational Hospital Portfolio & Capacity of Jupiter Life Line Hospitals (Q1 FY2027)
Jupiter Life Line Hospitals operates a network of major hospital facilities strategically located in key metropolitan and regional hubs.
- Total Installed Bed Capacity – 1,548 beds across 4 hospitals
- Operational Beds Capacity – 1,150+ beds
- Thane Hospital Capacity – 352 beds (Operational since 2007)
- Pune Hospital Capacity – 350 beds (Operational since 2017)
- Indore Hospital (Vishesh Jupiter) Capacity – 346 beds (Acquired & re-launched in 2020)
- Dombivli Hospital Capacity – 500 beds total capacity (Phase-I 200 operational beds launched Feb 2026)
The bed capacity expanded to 1,548 beds following the Phase-I operationalization of the Dombivli greenfield hospital in February 2026. The company operates on an "all-hub-no-spoke" model where each hospital functions as a full-service, standalone tertiary care unit.
Operational KPIs & Hospital Metrics of Jupiter Life Line Hospitals (Q1 FY2027)
Jupiter Life Line Hospitals tracks bed occupancy, average daily rates, and patient stays across its hospital network.
- Average Revenue Per Occupied Bed (ARPOB) – Rs 73,500 per day (+10.0% YoY)
- Average Length of Stay (ALOS) – 3.76 days
- Blended Portfolio Bed Occupancy Rate – 59.6% (Diluted by Dombivli addition)
- Mature Hospitals Occupancy Rate (Thane & Pune) – 65.0% to 75.0%
- Indore Unit Bed Occupancy Rate – ~50.0%
- Dombivli Unit Bed Occupancy Rate – 25.0% to 30.0% (First full quarter post-launch)
ARPOB expanded 10% year-on-year to Rs 73,500 per day in Q1 FY2027, driven by surgical case mix optimization and insurance contract renegotiations. Blended occupancy stood at 59.6% due to the initial capacity phase-in at Dombivli.
Hospital Specialty Revenue Mix of Jupiter Life Line Hospitals (FY2026)
Jupiter Life Line Hospitals derives its healthcare service revenues across a broad range of super-specialty medical fields.
- Cardiac Sciences & Cardiology Share – ~22.0% of Total Operating Revenue
- Oncology & Radiation Therapy Share – ~18.5% of Total Operating Revenue
- Neurosciences & Neurosurgery Share – ~14.0% of Total Operating Revenue
- Orthopaedics & Joint Replacement Share – ~12.5% of Total Operating Revenue
- Organ Transplants & Gastroenterology Share – ~11.0% of Total Operating Revenue
- Paediatrics, Gynaecology & Other Specialties Share – ~22.0% of Total Operating Revenue
Cardiac sciences and oncology lead the clinical revenue mix, supported by specialized robotic surgery suites and radiation therapy units. Comprehensive organ transplant suites across kidney, liver, and heart procedures further enhance high-end case realisations.
Payor Channel Mix & Patient Profile of Jupiter Life Line Hospitals (FY2026)
Jupiter Life Line Hospitals maintains a high-yielding payor structure dominated by self-pay cash patients and private insurance.
- Self-Pay Cash & Direct Outpatient Share – ~46.0% of Total Hospital Collections
- Private Health Insurance (TPA & Corporate) Share – ~48.0% of Total Hospital Collections
- Government Schemes Share – <2.0% of Total Hospital Collections
- International Medical Tourism Share – ~4.0% of Total Hospital Collections
Private cash walk-ins and commercial health insurance contribute over 94% of overall patient billings. The company maintains negligible exposure to low-margin government schemes, preserving operational cash conversion.
Latest Quarterly Financial Performance of Jupiter Life Line Hospitals (Q1 FY2027)
Jupiter Life Line Hospitals recorded top-line revenue expansion during the first quarter of FY2027, alongside temporary profit compression due to new unit drag.
- Total Revenue from Operations – Rs 410.98 crore (+18.2% YoY)
- Consolidated Operating EBITDA – Rs 79.30 crore (+5.2% YoY)
- Operating EBITDA Margin – 19.30% (Impacted by Rs 9.5 crore Dombivli drag)
- Consolidated Net Profit After Tax (PAT) – Rs 37.51 crore (-14.5% YoY)
- Dombivli Operational EBITDA Loss Drag – Rs 9.50 crore
First-quarter operating revenue rose 18.2% year-on-year to Rs 410.98 crore, driven by existing hospital performance and the Dombivli ramp-up. Consolidated Net Profit After Tax stood at Rs 37.51 crore, reflecting fixed cost drag and clinical staff additions at the newly operational Dombivli unit.
Consolidated Annual Financial Performance of Jupiter Life Line Hospitals (FY2026)
Jupiter Life Line Hospitals delivered full-year turnover expansion and operational earnings growth for full financial year FY2026.
- Full Year Total Income from Operations – Rs 1,185.40 crore (+14.2% YoY)
- Full Year Operating EBITDA – Rs 268.50 crore (+15.8% YoY)
- Full Year Operating EBITDA Margin – 22.65%
- Consolidated Net Profit After Tax (PAT) – Rs 162.40 crore (+18.5% YoY)
- Return on Capital Employed (ROCE) – 15.8%
Full-year total income expanded 14.2% in FY2026, while consolidated Net Profit After Tax reached Rs 162.40 crore. Financial execution was supported by ARPOB gains across mature units in Thane and Pune.
Balance Sheet Structure & Financial Health Ratios of Jupiter Life Line Hospitals (Q1 FY2027)
Jupiter Life Line Hospitals operates a zero-debt balance sheet structure backed by strong liquid cash reserves.
- Debt to Equity Ratio – Net Debt Zero / Net Cash Positive (0.00x)
- Total Cash, Bank Balances & Liquid Treasury Investments – ~Rs 500.00 crore
- Gross Financial Debt Base – ~Rs 500.00 crore (Offset by equivalent cash reserves)
- Total Consolidated Net Worth Base – ~Rs 1,650.00 crore
- Board Debt Gearing Ceiling Limit – 3.0x EBITDA maximum limit
The company maintains a net-zero debt position with cash reserves of ~Rs 500 crore fully offsetting gross capex debt. Unutilized bank credit lines and internal cash flows provide liquidity for ongoing hospital construction.
Capital Expenditure & Capacity Expansion Pipeline of Jupiter Life Line Hospitals (FY2027–FY2029)
Jupiter Life Line Hospitals executes a multi-year capital allocation plan to increase its total bed capacity from 1,548 to ~2,500 beds.
- Total Planned Multi-Year Capex Outlay – Rs 1,200–1,400 crore across ongoing projects
- Total Expansion Bed Pipeline Target – Adding 1,452+ beds to reach 2,500 beds
- Dombivli Hospital Expansion (Phase-II) – Scaling from 200 beds to full 500 beds capacity
- Greenfield Project (Bibvewadi, Pune) – 500-bed greenfield hospital (Targeted operationalization CY2028)
- Greenfield Project (Dera Bassi / Mohali) – 450-bed greenfield hospital (Targeted operationalization CY2029)
- Funding Strategy – Funded via internal operational cash accruals, liquid reserves, and phased bank debt
Multi-year capital outlays center on completing Phase-II bed fit-outs at Dombivli and constructing greenfield hospitals in Bibvewadi (Pune) and Dera Bassi. Internal cash flow conversion and liquid reserves fund early-stage land and civil works.
Strategic Outlook & Management Commentary of Jupiter Life Line Hospitals (Q1 FY2027 Concall)
Management guidance outlines strategic priorities focused on Dombivli unit break-even, Indore bed utilization, and brownfield margin expansion.
- Management targets achieving Dombivli unit EBITDA break-even within 1.5 to 2 years of operationalization.
- Dombivli monthly EBITDA drag is guided to remain around Rs 2 to 3 crore during FY2027 as doctor onboarding continues.
- Indore unit occupancy is projected to scale up from 50% through doctor additions during FY2027.
- Full clinical radiation oncology (LINAC) suites at Dombivli are targeted to launch by calendar year-end 2026.
- Capital allocation strategy will maintain net debt levels well within the 3.0x EBITDA board threshold throughout the capex cycle.
Management anticipates insurance empanelment at Dombivli to accelerate bed occupancy and revenue growth. Operational focus remains centered on ramping up new clinical specialties, scaling the Indore hospital, and advancing greenfield project construction in Pune.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Jupiter Life Line Hospitals Q1 FY2027 Earnings Call Summary & Analyst Transcript (August 2026)
- Jupiter Life Line Hospitals Q3 FY2026 Investor Presentation & NSE Filings (January 2026)
- BSE Limited & National Stock Exchange of India (NSE) Corporate Filings for Jupiter Life Line Hospitals
- Ticker Finology Jupiter Life Line Hospitals Page
Disclaimer
The information presented above on Jupiter Life Line Hospitals has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Jupiter Life Line Hospitals page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.